Study identity card

DisCoVeRy

Austria Belgium France Greece Luxembourg Norway Portugal
Share
  • Study type: Randomised Clinical Trial, Treatment
  • Study type descriptors: Randomised controlled trial, Multicentre
  • Objective: The DisCoVeRy study investigated the safety and effectiveness of the drug AZD7442 in hospitalized adults with COVID-19, comparing it to standard of care plus a placebo
  • Number of participants enrolled: 1552
  • Study enrolling from to
  • Study includes follow-up for 15 months

Study Data

  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Tixagevimab/Cilgavimab
  • Hydroxychloroquine
  • Interferon Beta-1A
  • Lopinavir/ritonavir

Other information

If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it

The data is updated up to